|
|
|
|
Beads give young cancer patients a way to measure their journey
By Mara Corts Gonzlez El Paso Times EL PASO -- The string of colorful beads around Aiyana Hanson's neck is starting to weigh on her.But she would never think of removing a single one. She has earned each bead with every prick of her skin, blood...
|
|
|
Mexican firms start planting GM corn, activists appeal
The corn was coming up different ...It was no good anymore. Florencio Cruz Cortes, farmer Capping a decade-long battle, private companies in Mexico have begun the first legal plantings of genetically modified (GM) corn, the Department of Agriculture...
|
|
|
Mexico starts planting GM corn, activists appeal
MEXICO CITY (AP) -- Capping a decade-long battle, private companies in Mexico have begun the first legal plantings of genetically modified corn, the Agriculture Department said Wednesday.Environmentalists and farm groups announced they have filed an appeal with...
|
|
|
Mexico Starts Planting Genetically Modified Corn
MARK STEVENSON, Associated Press Writer MEXICO CITYCapping a decade-long battle, private companies in Mexico have begun the first legal plantings of genetically modified corn, the Agriculture Department said Wednesday.Environmentalists and farm groups...
|
|
|
Mexico starts planting of GM corn, activists appeal to regional rights commission
MEXICO CITY Capping a decade-long battle, private companies in Mexico have begun the first legal plantings of genetically modified corn, the Agriculture Department said Wednesday.Environmentalists and farm groups announced they have filed an appeal with the...
|
|
|
Mexico starts planting GM corn, activists appeal
MEXICO CITY (AP) Capping a decade-long battle, private companies in Mexico have begun the first legal plantings of genetically modified corn, the Agriculture Department said Wednesday.Environmentalists and farm groups announced they have filed an appeal with...
|
|
|
Mexico starts planting GM corn, activists appeal
MEXICO CITY -- Capping a decade-long battle, private companies in Mexico have begun the first legal plantings of genetically modified corn, the Agriculture Department said Wednesday.Environmentalists and farm groups announced they have filed an appeal with...
|
|
|
Mexico Starts Planting GM Corn, Activists Appeal
MARK STEVENSON, Associated Press Writer MEXICO CITY (AP) Capping a decade-long battle, private companies in Mexico have begun the first legal plantings of genetically modified corn, the Agriculture Department said Wednesday.Environmentalists and farm groups...
|
|
|
Mexico starts planting GM corn, activists appeal
Capping a decade-long battle, private companies in Mexico have begun the first legal plantings of genetically modified corn, the Agriculture Department said Wednesday.Environmentalists and farm groups announced they have filed an appeal with the Inter...
|
|
|
Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positiv
Jos Baselga,* Karen A.Gelmon, Shailendra Verma, Andrew Wardley, PierFranco Conte, David Miles, Giulia Bianchi, Javier Cortes, Virginia A. McNally, Graham A. Ross, Pierre Fumoleau, and Luca Gianni From the Vall d'Hebron Institute of Oncology, Vall d...
|
|
|
Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzuma
Luca Gianni,* Anna Llad, Giulia Bianchi, Javier Cortes, Pirkko-Liisa Kellokumpu-Lehtinen, David A.Cameron, David Miles, Stefania Salvagni, Andrew Wardley, Jean-Charles Goeminne, Veronica Hersberger, and Jos Baselga From the Fondazione Istituto Di...
|
|
|
Select Topics in ALL: Molecular Characterization, Approaches to CNS Disease, and Post-remission Transplantatio
Complimentary Continuing Education Virtual Lecture for Healthcare Professionals VOORHEES, N.J., Feb.1 /PRNewswire/ -- Treating acute lymphocytic leukemia (ALL) can bring many challenges, particularly in the adult population. To optimally manage this...
|
|
|
Select Topics in ALL: Molecular Characterization, Approaches to CNS Disease, and Post-remission Transplantatio
Complimentary Continuing Education Virtual Lecture for Healthcare Professionals VOORHEES, N.J., Feb.1 /PRNewswire/ -- Treating acute lymphocytic leukemia (ALL) can bring many challenges, particularly in the adult population. To optimally manage this...
|
|
|
Wash. unemployment rate jumps to 9.5 percent
By RACHEL LA CORTE - Associated Press Writer - Associated Press Wednesday, January 20, 2010 Washington's unemployment rate jumped to 9.5 percent in December, the state's highest rate since 1984, state officials said Wednesday.Dave Wallace, chief...
|
|
|
Long service (2009)
John Michael Williams, of Marlow David Pierce Williams, of Dolgellau Honora Bridget Mary Frenzel, of Chesterfield Michael Colin Marchant Roedel, of Enfield Derek Power, of Taunton John Michael Newton, of London Gordon Cort Jefferson, of Edi Long service ...
|
|
|
Corcept Therapeutics Announces Four Anticipated Milestones for 2010
MENLO PARK, CA -- (MARKET WIRE) -- 01/05/10 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders, announces its...
|
|
|
Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
Potential to Support U.S.Regulatory Filing SAN DIEGO, Dec. 11 /PRNewswire/ -- Ambit Biosciences Corporation announced today the enrollment and dosing at the University of Texas M. Anderson Cancer Center of the first patient in the ACE (AC220 Monotherapy...
|
|
|
Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
See more news releases in: Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Clinical Trials & Medical Discoveries Potential to Support U.S.Regulatory Filing SAN DIEGO, Dec. 11 /PRNewswire/ -- Ambit Biosciences Corporation...
|
|
|
Drug Shows Promise for T315I-Mutated Chronic Myeloid Leukemia
Omacetaxine launches different attack on CML that is impervious to other therapies NEW ORLEANS Results from a phase II clinical trial indicate a novel drug may provide a treatment option for chronic myeloid leukemia (CML) patients who do not respond to current...
|
|
|
Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukem
SAN DIEGO, Dec.7 /PRNewswire/ -- Ambit Biosciences Corporation announced today that preliminary results from a clinical trial of its lead product candidate, AC220, in acute myeloid leukemia (AML) were presented at the 51st Annual Meeting of the American...
|
|
|
ARIAD to Present Data on Pan-BCR-ABL Inhibitor AP24534 at 51st American Society of Hematology Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc.(NASDAQ: ARIA - News) today announced that the Company and collaborating investigators from five major oncology research centers in the United States will present data from a Phase 1 clinical...
|
|
|
ARIAD to Present Data on Pan-BCR-ABL Inhibitor AP24534 at 51st American Society of Hematology Meeting
- (NASDAQ: ARIA) today announced that the Company and collaborating investigators from five major oncology research centers in the United States will present data from a Phase 1 clinical trial of ARIAD's investigational, multi-targeted kinase inhibitor and pan...
|
|
|
ARIAD to Present Data on Pan-BCR-ABL Inhibitor AP24534 at 51st American Society of Hematology Meeting
Company Website: http:www.ariad.comCAMBRIDGE, Mass.-- (Business Wire) (NASDAQ: ARIA) today announced that the Company and collaborating investigators from five major oncology research centers in the United States will present data from a Phase 1 clinical...
|
